



### Raising TP to SAR 29.0 on improved performance of Al Nuzha Hospital

We raise our TP for Al Hammadi Company for Development and Investment (Al Hammadi) to **SAR 29.0/share** from SAR 26.0, as the company benefits from an improved performance of Al Nuzha Hospital. The strong Q3-20 results can be attributed to the higher number of patients admitted during the period due to transfers from MoH, improvement in performance of Al Nuzha Hospital, and higher operating efficiency. We update our EPS estimate for FY20 to SAR 1.08 from SAR 1.01 to factor in the improved performance in Q3-20, along with the above factors. We maintain our **“Neutral”** rating on the stock.

- FY20 EPS raised to reflect better-than-expected results in Q3-20 and enhanced performance of Al Nuzha Hospital:** Based on Q3-20 results that exceeded expectations, we raise our EPS estimates for FY20 to SAR 1.08 from SAR 1.01. Al Hammadi reported a Q3-20 revenue of SAR 249.0mn (13.2% Y/Y) and EPS of SAR 0.30 (72.7% Y/Y). EPS exceeded the consensus estimate of SAR 0.25 and our estimate of SAR 0.22, driven mainly by a 160 bps beat on operating margin. Patient traffic increased as most people opted to stay in the country to avoid contracting the virus while travelling. This led to significant growth in revenue, that was further aided by an increase in referrals from the MoH which improved performance from Al Nuzha Hospital. However, we believe the current rate of earnings growth would not be sustainable.
- Positive contribution from Al Nuzha Hospital likely to reflect onto margins:** Al Hammadi commenced operations at Al Nuzha Hospital (120 beds) in Q1-18. The hospital generated an improved performance in Q3-20, which would positively affect its margins. The hospital has a capacity of 600 beds and 64 clinics. As hospital operations have returned to pre-COVID levels with the lifting of lockdown restrictions, we expect the company to gradually ramp up operations with the increase in demand. We modelled a GP Margin of 31.1% and 32.4% for FY21 and FY22, respectively.
- Government initiatives to support the private sector drove a margin increase in Q3-20:** The government extended support to the private sector through the SANED program, wherein it covered a part of employee costs. This favorably impacted the company's operating margin in Q3-20. Once the program ends, we expect margins to decline from current levels.

**AJC view and valuation:** Al Hammadi's revenue growth and margins will likely moderate from current levels in our view. As FY20 had few one-time benefits such as high inpatient admissions due to COVID-19 and most people abandoning vacation plans to stay in country to avoid infection, Al Hammadi's earnings growth would decrease in FY21. The improvement in capacity utilization at Al-Nuzha Hospital is the key revenue driver for the company. Margins should improve gradually with the stabilization of operations at Al-Nuzha Hospital. High exposure to receivables from MoH would put pressure on working capital requirement, likely leading to high debt. We raise our estimates and TP to reflect the benefits the company accrued during 9M-20. However, we believe most of the positives are factored in at the current levels, and buying opportunities would be available once the stock corrects from the current levels.

We value Al Hammadi on 50% weightage for DCF (3.0% terminal growth and 8.2% average WACC) and 25% weightage each for EV/EBITDA (15.1x FY21 EBITDA) and P/E (22.9x FY21 EPS) based on relative valuation. These yield a TP of **SAR 29.0/share**, implying a 1.5% downside from the current levels. The stock is currently trading at P/E of 24.7x based on our FY21 EPS estimate. We maintain our **“Neutral”** rating on this stock.

## Neutral

**Target Price (SAR)** 29.0

**Upside / (Downside)\*** -1.5%


Source: Tadawul \*prices as of 3<sup>rd</sup> of December 2020

### Key Financials

SARmn (unless specified)	FY19	FY20E	FY21E
Revenue	974.1	979.3	1,061.7
Growth %	9.0%	0.5%	8.4%
Gross Profit	282.6	324.9	329.8
Net Profit	93.0	129.6	142.9
Growth %	3.5%	39.3%	10.3%
EPS	0.77	1.08	1.19

Source: Company reports, Aljazira Capital

### Price Performance



Source: Company reports, Aljazira Capital, Bloomberg

### Key Ratios


	FY19	FY20E	FY21E
GP Margin	29.0%	33.2%	31.1%
Net Margin	9.5%	13.2%	13.5%
P/E (x)	27.1	27.3	24.7
P/B (x)	1.6	2.1	1.9
EV/EBITDA (x)	16.2	13.9	12.8

### Key Market Data

Market Cap( SAR bn)	3.5
YTD%	40.0%
52 week (High)/(Low)	31.8/16.7
Share Outstanding (mn)	120.0

Source: Company reports, Aljazira Capital

### Price Performance



Source: Company reports, Aljazira Capital, Bloomberg

Head of Research

Talha Nazar

+966 11 2256250

t.nazar@aljaziracapital.com.sa

## Investment Update

## Key Financial Data

Amount in SAR mn, unless otherwise specified	FY16	FY17	FY18	FY19	FY20E	FY21E	FY22E
<b>Income statement</b>							
Revenues	606.2	708.6	893.6	974.1	979.3	1,061.7	1,150.4
<b>Y/Y</b>	<b>8.0%</b>	<b>16.9%</b>	<b>26.1%</b>	<b>9.0%</b>	<b>0.5%</b>	<b>8.4%</b>	<b>8.4%</b>
Cost	(364.1)	(469.5)	(643.2)	(691.4)	(654.4)	(731.9)	(777.4)
<b>Gross profit</b>	<b>242.1</b>	<b>239.2</b>	<b>250.4</b>	<b>282.6</b>	<b>324.9</b>	<b>329.8</b>	<b>373.0</b>
Operating Expenses	(143.3)	(112.3)	(123.1)	(153.0)	(157.2)	(155.6)	(163.5)
SG&A Expenses	(143.3)	(112.3)	(123.1)	(153.0)	(123.2)	(135.6)	(143.5)
Impairment losses on trade receivable	-	-	-	-	(34.0)	(20.0)	(20.0)
<b>Other operating Income/(expense)</b>	<b>4.2</b>	<b>15.7</b>	<b>10.9</b>	<b>17.0</b>	<b>11.1</b>	<b>12.0</b>	<b>12.0</b>
<b>Operating profit</b>	<b>103.0</b>	<b>142.6</b>	<b>138.1</b>	<b>146.5</b>	<b>178.8</b>	<b>186.2</b>	<b>221.6</b>
<b>Y/Y</b>	<b>-32.8%</b>	<b>38.4%</b>	<b>-3.1%</b>	<b>6.1%</b>	<b>22.0%</b>	<b>4.2%</b>	<b>19.0%</b>
Financing Expense	(19.0)	(19.6)	(33.4)	(37.1)	(30.6)	(24.3)	(17.1)
<b>Income before zakat</b>	<b>84.0</b>	<b>123.0</b>	<b>104.7</b>	<b>109.5</b>	<b>148.2</b>	<b>161.9</b>	<b>204.4</b>
Zakat	(11.0)	(15.1)	(14.9)	(16.5)	(18.6)	(19.0)	(23.9)
<b>Net income</b>	<b>73.0</b>	<b>108.0</b>	<b>89.8</b>	<b>93.0</b>	<b>129.6</b>	<b>142.9</b>	<b>180.5</b>
<b>Y/Y</b>	<b>-44.5%</b>	<b>48.0%</b>	<b>-16.8%</b>	<b>3.5%</b>	<b>39.3%</b>	<b>10.3%</b>	<b>26.3%</b>
<b>Balance sheet</b>							
<b>Assets</b>							
Cash & equivalent	13	178	44	76	206	184	256
Other current assets	479	327	622	668	589	582	596
Non-current assets	1,651	1,798	1,819	1,817	1,814	1,842	1,865
Property plant & equipment	1,651	1,798	1,787	1,739	1,729	1,756	1,777
Other non-current assets	-	-	31	55	58	59	60
<b>Total assets</b>	<b>2,142</b>	<b>2,303</b>	<b>2,484</b>	<b>2,538</b>	<b>2,582</b>	<b>2,581</b>	<b>2,688</b>
<b>Liabilities &amp; owners' equity</b>							
Total current liabilities	213	230	235	325	297	275	289
Long-term loans	371	483	563	430	385	259	169
Total other non-current liabilities	189	203	208	217	204	208	211
Paid -up capital	1,200	1,200	1,200	1,200	1,200	1,200	1,200
Statutory reserves	22	33	42	51	64	78	96
Retained earnings	148	154	237	315	432	560	723
Total owners' equity	1,370	1,387	1,479	1,566	1,696	1,839	2,019
<b>Total equity &amp; liabilities</b>	<b>2,142</b>	<b>2,303</b>	<b>2,484</b>	<b>2,538</b>	<b>2,582</b>	<b>2,581</b>	<b>2,688</b>
<b>Cashflow statement</b>							
Operating activities	(42)	310	(52)	183	300	275	287
Investing activities	(145)	(197)	(118)	(45)	(91)	(130)	(124)
Financing activities	111	52	35	(106)	(78)	(166)	(91)
Change in cash	(76)	166	(134)	32	130	(22)	72
<b>Ending cash balance</b>	<b>13</b>	<b>178</b>	<b>44</b>	<b>76</b>	<b>206</b>	<b>184</b>	<b>256</b>
<b>Key fundamental ratios</b>							
<b>Liquidity ratios</b>							
Current ratio (x)	2.3	2.2	2.8	2.3	2.7	2.8	2.9
Quick ratio (x)	2.2	2.1	2.6	2.1	2.5	2.6	2.8
<b>Profitability ratios</b>							
Gross profit margin	39.9%	33.7%	28.0%	29.0%	33.2%	31.1%	32.4%
Operating margin	17.0%	20.1%	15.5%	15.0%	18.3%	17.5%	19.3%
<b>EBITDA margin</b>	<b>25.8%</b>	<b>27.6%</b>	<b>25.4%</b>	<b>25.6%</b>	<b>28.3%</b>	<b>27.2%</b>	<b>28.1%</b>
Net profit margin	12.0%	15.2%	10.1%	9.5%	13.2%	13.5%	15.7%
Return on assets	3.6%	4.9%	3.8%	3.7%	5.1%	5.5%	6.9%
<b>Return on equity</b>	<b>5.3%</b>	<b>7.8%</b>	<b>6.3%</b>	<b>6.1%</b>	<b>7.9%</b>	<b>8.1%</b>	<b>9.4%</b>
<b>Leverage ratio</b>							
Debt / equity (x)	0.35	0.38	0.45	0.37	0.30	0.19	0.13
<b>Market/valuation ratios</b>							
EV/sales (x)	9.0	6.8	4.1	4.1	3.9	3.5	3.1
EV/EBITDA (x)	34.9	24.6	16.0	16.2	13.9	12.8	10.9
EPS (SAR)	0.6	0.9	0.7	0.8	1.1	1.2	1.5
BVPS (SAR) - Adjusted	11.4	11.6	12.3	13.1	14.1	15.3	16.8
Market price (SAR)*	41.53	37.10	25.10	21.00	29.45	29.45	29.45
Market-Cap (SAR mn)	4,983.6	4,452.0	3,012.0	2,520.0	3,534.0	3,534.0	3,534.0
Dividend yield	1.8%	0.0%	3.0%	0.0%	0.0%	0.0%	0.0%
P/E ratio (x)	68.3	41.2	33.5	27.1	27.3	24.7	19.6
P/BV ratio (x)	3.6	3.2	2.0	1.6	2.1	1.9	1.8

Source: Company financials, AlJazira research



RESEARCH DIVISION

AGM-Head of Research

Talha Nazar

+966 11 2256250  
t.nazar@aljaziracapital.com.sa

Analyst

Faisal Alsuwelimy

+966 11 2256115  
F.alsuweilmy@aljaziracapital.com.sa

Senior Analyst

Jassim Al-Jubran

+966 11 2256248  
j.aljabran@aljaziracapital.com.sa

Analyst

Abdulrahman Al-Mashal

+966 11 2256374  
A.Almashal@Aljaziracapital.com.sa

BROKERAGE AND INVESTMENT CENTERS DIVISION

General Manager – Brokerage Services & sales

Alaa Al-Yousef

+966 11 2256060  
a.yousef@aljaziracapital.com.sa

AGM-Head of international and institutions

Ahmad Salman, CFA

+966 11 2256201  
a.salman@aljaziracapital.com.sa

AGM-Head of Qassim & Eastern Province

Abdullah Al-Rahit

+966 16 3617547  
aalrahit@aljaziracapital.com.sa

AGM-Head of Central & Western Region

Investment Centers

Sultan Ibrahim AL-Mutawa

+966 11 2256364  
s.almutawa@aljaziracapital.com.sa

RESEARCH DIVISION

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING TERMINOLOGY

1. **Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
2. **Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
3. **Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
4. **Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

## Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. This report has been written by professional employees in Al-Jazira Capital, and they undertake that neither them, nor their wives or children hold positions directly in any listed shares or securities contained in this report during the time of publication of this report, however, The authors and/or their wives/children of this document may own securities in funds open to the public that invest in the securities mentioned in this document as part of a diversified portfolio over which they have no discretion. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.